The sharp reduction in losses and return to revenue via a licensing deal signal operational stabilization after a turnaround. Monitor upcoming clinical data readouts and IND submission timing for vebreltinib, which could catalyze further upside despite limited cash reserves.
Price Chart
Executive Summary
Apollomics reported its 2025 full-year financial results, posting $8.5M in revenue from a licensing deal with LaunXP, a significant improvement from $0 in 2024. The company reduced operating expenses by 64% year-over-year and ended 2025 with $3.3M in cash, though net loss narrowed to $(10.9M) from $(53.9M) in 2024. Pipeline progress includes advancing vebreltinib in global Phase 2 trials and planning a U.S. IND submission by 2027.
Key Financial Metrics
Key Facts
- Revenue for 2025 was $8.5 million (vs. $0 in 2024), driven by upfront payment from LaunXP licensing agreement.
- Operating expenses dropped 64% YoY to $19.8M from $55.7M in 2024, due to cost reduction initiatives.
- Net loss narrowed significantly to $(10.9M) in 2025 from $(53.9M) in 2024.
- Cash balance was $3.3M as of December 31, 2025, down from $9.8M at end of 2024.
- Vebreltinib (APL-101) is in ongoing global Phase 2 SPARTA trial with over 282 patients enrolled; U.S. IND submission planned for first half of 2027.
Financial Impact
$8.5M in new licensing revenue, operating expenses cut by $35.9M YoY
Risk Factors
- Cash balance of $3.3M may not be sufficient to fund ongoing global trials without dilutive financing.
- Revenue was non-recurring (upfront licensing payment), so future top-line growth depends on new deals or approvals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281561 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 9w ago | Insider Cluster | $23.92 $26.50 | ▲ +10.79% | ▲ +10.99% | $19.90 (−16.81%) |
Aug 17, 2026 9w ago | Insider Cluster | $23.92 $26.50 | ▲ +10.79% | ▲ +10.99% | $19.90 (−16.81%) |
Aug 17, 2026 9w ago | Insider Cluster | $23.92 $26.50 | ▲ +10.79% | ▲ +10.99% | $19.90 (−16.81%) |
Aug 17, 2026 9w ago | Insider Cluster | $23.92 $26.50 | ▲ +10.79% | ▲ +10.99% | $19.90 (−16.81%) |
Jul 21, 2026 13w ago | 6-K | $18.71 $18.00 | ▼ −3.77% | ▼ −2.54% | $19.90 (+6.39%) |
Jul 14, 2026 14w ago | 6-K | $15.70 $18.86 | ▲ +20.13% | ▲ +21.42% | $19.90 (+26.75%) |
Jun 24, 2026 17w ago | 6-K | $22.00 $20.16 | ▲ +8.36% | ▲ +9.92% | $19.90 (+9.55%) |
Apr 27, 2026 26w ago | Press Release | $13.19 $16.47 | ▲ +24.84% | ▲ +24.44% | $19.90 (+50.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers